G01N 2333/145
Rhabdoviridae
Official title: Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
G01N2333/145 (Rhabdoviridae) appears on 13 US grants and 19 published applications in this corpus.
Search patents in G01N- Granted patents
- 13
- Published applications
- 19
- Assignees
- 22
- Inventors
- 58
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 1 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 1 | 0 |
| 2015 | 1 | 2 |
| 2016 | 1 | 1 |
| 2017 | 1 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 2 |
| 2024 | 1 | 4 |
| 2025 | 0 | 0 |
| 2026 | 2 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Hybridoma cell line for secreting anti-rabies virus M protein monoclonal antibody and application thereof5 May 2026US 12,617,840 B2Zhejiang University
- Detection assays for coronavirus neutralizing antibodies20 Jan 2026US 12,529,699 B2Regeneron Pharmaceuticals, Inc.
- Polypeptides useful for detecting anti-rhabdovirus antibodies2 Jan 2024US 11,858,962 B2
- Identification of antibodies specific for lyssaviruses and methods of their use3 Sep 2019US 10,400,031 B2The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
- Identification of antibodies specific for at least two different lyssaviruses7 Nov 2017US 9,809,643 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Hybridoma cell line for secreting anti-rabies virus m protein monoclonal antibody and application thereof8 Aug 2024US 2024/0262891 A1Zhejiang University
- Pharmaceutical composition for preventing or treating virus infections, comprising polymer nanodiscs20 Jun 2024US 2024/0197634 A1Mvrix Co., Ltd.
- Compositions and methods for tracing cell networks9 May 2024US 2024/0151709 A1The Brigham and Women S Hospital, Inc.
- Evaluation method of pathogen inactivation effect4 Jan 2024US 2024/0002899 A1Institute of Blood Transfusion CAMS
- Compositions, methods, and systems for detecting immune response5 Oct 2023US 2023/0314432 A1Covid Diagnostics Ltd.
Most cited
By later US patents
- Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents37US 6,635,416 B2Mount Sinai School of Medicine of New York University · 2003
- Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents26US 7,442,527 B2Mount Sinai School of Medicine of New York University · 2008
- Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents23US 7,060,430 B2Mount Sinai School of Medicine of New York University · 2006
- Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents20US 7,833,774 B2Mount Sinai School of Medicine of New York University · 2010